{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-053987","form_type":"8-K","ticker":"ORKA","cik":"0000907654","company_name":"Oruka Therapeutics, Inc.","filed_at":"2023-10-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:32.354010+00:00","generated_at":"2026-06-09T22:17:30.331850+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ARCA biopharma reports Q3 2023 net loss of $1.4M; cash $38.5M sufficient through end of 2024","bullets":["Net loss of $1.4M ($0.10/share) vs $2.3M ($0.16/share) in Q3 2022; operating expenses down to $2.0M from $2.6M.","Cash and equivalents $38.5M at Sep 30, 2023 (down from $42.4M at Dec 31, 2022); funding runway through end of 2024.","R&D expenses fell to $0.3M from $1.0M YoY due to prior 67% workforce reduction (12 employees) in July 2022.","Strategic review process with Ladenburg Thalmann continues; no defined timeline and may not result in a transaction."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-053987","json":"https://secwatch.observer/filing/0000950170-23-053987.json","markdown":"https://secwatch.observer/filing/0000950170-23-053987.md","text":"https://secwatch.observer/filing/0000950170-23-053987.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/907654/000095017023053987/0000950170-23-053987-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/907654/000095017023053987/abio-20231018.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T22:17:30.331850+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3e2e19b8b73eb1da83d5978a6be9f8bcbf106070","claim":"Oruka Therapeutics, Inc. reported quarter ended September 30, 2023 results: net income $1.4 million, EPS $0.10 per basic and diluted share.","evidence_excerpt":"Net loss for the quarter ended September 30, 2023 was $1.4 million, or $0.10 per basic and diluted share, compared to $2.3 million, or $0.16 per basic and diluted share in the third quarter of 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/907654/000095017023053987/0000950170-23-053987-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"quarter ended September 30, 2023"},{"label":"Net income","value":"$1.4 million"},{"label":"EPS","value":"$0.10 per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}